HHS Recommends Cannabis (Article Clips + Letter to DEA)Not too sure how many folks actually took the time to research the HHS Letter of Recommendation to Reschedule Cannabis however, due to mis-statements made on this forum today I am opting to put out the facts in case there are a few out there trading in potentially the wrong direction.
Below are
CLIPS from the article I link to at the bottom of the post. For the full article use the link to see it all.
Do some folks a favor, if you are on mutiple forums then copy and paste this post and share it or simply share a link - Cannabis Bulls thank you.
(Article) HHS Releases Unredacted Report Recommending Cannabis Rescheduling "On August 29, 2023, the U.S. Department of Health and Human Services (HHS) submitted an analysis to the Drug Enforcement Agency (DEA) recommending that cannabis be rescheduled as a Schedule III controlled substance. HHS finally made this report public in its unredacted form last Friday" "... enough data for HHS to conclude, in the totality, that medicinal use of cannabis has scientific support. HHS also considered the use of cannabis in the treatment of anxiety, epilepsy, PTSD, and inflammatory bowel disease ... " Link to full Article https://www.shipmangoodwin.com/insights/hhs-releases-unredacted-report-recommending-cannabis-rescheduling.html Clip from HHS Letter of Recommendation to Reschedule To Schedule III (Page 25) In Part 1 of the CAMU test, OASH identified at least 15 medical conditions where there is widespread current experience with medical use of the substance in the United States by licensed HCPs operating in accordance with implemented state authorized programs, where the medical use is recognized by entities that regulate the practice of medicine.
These conditions include amyotrophic lateral sclerosis (ALS), autism, cachexia, cancer, chronic pain, Crohn’s disease, epilepsy or condition causing seizures, glaucoma, HIV/AIDs, multiple sclerosis, Parkinson’s disease, persistent/severe muscle spasm, persistent/severe nausea, PTSD, and spasticity. FDA conducted Part 2 of the analysis for the medical conditions identified by OASH that were likely to have the most robust evidence available for review; because the analysis concluded that the Part 2 test has been met for at least one of the conditions identified in Part 1, there was no need to analyze all of them
Link to: BASIS FOR THE RECOMMENDATION TO RESCHEDULE MARIJUANA IN TO SCHEDULE III
OF THE CONTROLLED SUBSTANCES ACT
https://www.dropbox.com/scl/fi/pw3rfs9gm6lg80ij9tja6/2023-01171-Supplemental-Release-1.pdf?rlkey=v5atj0tcnhxhnszyyzcwdcvvt&dl=0